問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

顏志傑

Recruiting

List

103Cases

2023-01-30 - 2028-11-27

Phase II

Active
A Phase II, Open-Label, Multi-Drug, Multi-Center, Master Protocol to Evaluate the Efficacy and Safety of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer (GEMINI-Hepatobiliary)

  • Condition/Disease

    Hepatocellular Carcinoma

  • Test Drug

    MEDI5752 AVASTIN LENVIMA AZD2936

Participate Sites
8Sites

Recruiting8Sites

2022-12-01 - 2026-06-30

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2020-06-26 - 2026-12-31

Phase I/II

Active
A Phase 1b/2 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Trastuzumab Deruxtecan (T-DXd) Monotherapy and Combinations in Adult Participants with HER2-Overexpressing Gastric Cancer (DESTINY-Gastric03)

  • Condition/Disease

    HER2 overexpressing locally advanced or metastatic, unresectable Gastric Cancer.

  • Test Drug

    Trastuzumab Deruxtecan

Participate Sites
6Sites

Recruiting6Sites

2023-11-01 - 2027-12-31

Phase II

Active
A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination with Anti-cancer Agents in Participants with Advanced Solid Tumours Expressing Claudin 18.2.

  • Condition/Disease

    Gastric Cancer Gastroesophageal Junction Cancer Pancreatic Adenocarcinoma

  • Test Drug

    AZD0901

Participate Sites
5Sites

Recruiting4Sites

2022-09-01 - 2024-12-20

Phase I

Completed
Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of the Anti OX40 Agonist Monoclonal Antibody BGB-A445 in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors

  • Condition/Disease

    Advanced Solid Tumor、 Non Small Cell Lung Cancer 、Head and Neck Squamous Cell Carcinoma (HNSCC) 、Nasopharyngeal Carcinoma (NPC)

  • Test Drug

    BGB-A317BGB-A445

Participate Sites
4Sites

Recruiting4Sites

2023-07-01 - 2026-01-31

Phase II

Active
A Randomized, Phase 2, Open-Label, Multi-Arm Study of Tislelizumab in Combination With Investigational Agents as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

  • Condition/Disease

    Head and Neck Squamous Cell Carcinoma、 Head and Neck Cancer

  • Test Drug

    BGB-A317 (Tislelizumab); BGB-A425; LBL-007

Participate Sites
4Sites

Not yet recruiting2Sites

Recruiting2Sites

2024-06-01 - 2027-12-31

Phase I

Active
A Phase 1, First-in-Human, Open-label, Dose- escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ASD141 in Subjects with Advanced Solid Tumors

  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    injection

Participate Sites
3Sites

Recruiting3Sites

2024-03-13 - 2028-03-13

Phase I

Active
A Phase I Open-label Dose-finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of LXP1788 Injection in Patients with Advanced Solid Tumors.

  • Condition/Disease

    Solid Tumor Malignancies, Cancer

  • Test Drug

    注射劑

Participate Sites
2Sites

Recruiting2Sites

2022-06-01 - 2029-09-30

Phase I/II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2024-12-01 - 2031-05-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

1 2 3 4 5 11
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB